Darzalex daratumumab: Interim Phase III data

Interim data from the open-label, international Phase III POLLUX (MMY3003) trial in 569 patients with relapsed or refractory MM who received >=1 prior line of therapy showed that Darzalex plus Revlimid lenalidomide and dexamethasone met the

Read the full 369 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE